Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.
Schmelz K, Toedling J, Huska M, Cwikla MC, Kruetzfeldt LM, Proba J, Ambros PF, Ambros IM, Boral S, Lodrini M, Chen CY, Burkert M, Guergen D, Szymansky A, Astrahantseff K, Kuenkele A, Haase K, Fischer M, Deubzer HE, Hertwig F, Hundsdoerfer P, Henssen AG, Schwarz RF, Schulte JH, Eggert A. Schmelz K, et al. Among authors: astrahantseff k. Nat Commun. 2021 Nov 23;12(1):6804. doi: 10.1038/s41467-021-26870-z. Nat Commun. 2021. PMID: 34815394 Free PMC article.
Biological effects of TrkA and TrkB receptor signaling in neuroblastoma.
Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Limpt Vv, Sieverts H, Kuhfittig-Kulle S, Pfeiffer P, Versteeg R, Eggert A. Schramm A, et al. Among authors: astrahantseff k. Cancer Lett. 2005 Oct 18;228(1-2):143-53. doi: 10.1016/j.canlet.2005.02.051. Cancer Lett. 2005. PMID: 15921851 Review.
Application of microarray-based technology to neuroblastoma.
Scaruffi P, Valent A, Schramm A, Astrahantseff K, Eggert A, Tonini GP. Scaruffi P, et al. Among authors: astrahantseff k. Cancer Lett. 2005 Oct 18;228(1-2):13-20. doi: 10.1016/j.canlet.2005.01.052. Cancer Lett. 2005. PMID: 15951106 Review.
MYCN regulates oncogenic MicroRNAs in neuroblastoma.
Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A, Berwanger B. Schulte JH, et al. Among authors: astrahantseff k. Int J Cancer. 2008 Feb 1;122(3):699-704. doi: 10.1002/ijc.23153. Int J Cancer. 2008. PMID: 17943719 Free article.
Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH, Schulte S, Heukamp LC, Astrahantseff K, Stephan H, Fischer M, Schramm A, Eggert A. Schulte JH, et al. Among authors: astrahantseff k. Klin Padiatr. 2013 Nov;225(6):303-8. doi: 10.1055/s-0033-1357132. Epub 2013 Oct 28. Klin Padiatr. 2013. PMID: 24166094 Review.
A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.
Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprüssel A, Lindner S, De Preter K, Florin A, Heukamp LC, Klein-Hitpass L, Astrahantseff K, Kumps C, Speleman F, Eggert A, Westermann F, Schramm A, Schulte JH. Althoff K, et al. Among authors: astrahantseff k. Oncogene. 2015 Jun;34(26):3357-68. doi: 10.1038/onc.2014.269. Epub 2014 Sep 1. Oncogene. 2015. PMID: 25174395 Free PMC article.
ALK pERKs up MYCN in neuroblastoma.
Lindner S, Henssen A, Astrahantseff K, Schulte JH. Lindner S, et al. Among authors: astrahantseff k. Sci Signal. 2014 Oct 28;7(349):pe27. doi: 10.1126/scisignal.2005940. Sci Signal. 2014. PMID: 25351246
Mutational dynamics between primary and relapse neuroblastomas.
Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH. Schramm A, et al. Among authors: astrahantseff k. Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29. Nat Genet. 2015. PMID: 26121086
Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center.
Temming P, Arendt M, Viehmann A, Eisele L, Le Guin CH, Schündeln MM, Biewald E, Astrahantseff K, Wieland R, Bornfeld N, Sauerwein W, Eggert A, Jöckel KH, Lohmann DR. Temming P, et al. Among authors: astrahantseff k. Pediatr Blood Cancer. 2017 Jan;64(1):71-80. doi: 10.1002/pbc.26193. Epub 2016 Aug 27. Pediatr Blood Cancer. 2017. PMID: 27567086
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, de Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wünschel J, Pfeil S, Ercu M, Künkele A, Hu J, Thole T, Schweizer L, Mechtersheimer G, Carter D, Cheung BB, Popanda O, von Deimling A, Koster J, Versteeg R, Schwab M, Marshall GM, Speleman F, Erb U, Zoeller M, Allgayer H, Simon T, Fischer M, Kulozik AE, Eggert A, Witt O, Schulte JH, Deubzer HE. Fabian J, et al. Among authors: astrahantseff k. Oncotarget. 2016 Oct 11;7(41):66344-66359. doi: 10.18632/oncotarget.11662. Oncotarget. 2016. PMID: 27572323 Free PMC article.
38 results